Novavax DEF 14A: Executive Compensation Details
Ticker: NVAX · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1000694
| Field | Detail |
|---|---|
| Company | Novavax Inc (NVAX) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: NVVX
TL;DR
NVX proxy filing out - exec comp details for 2024 are in. Check equity awards.
AI Summary
Novavax Inc. filed its DEF 14A, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to both PEO (Principal Executive Officer) and Non-PEO NEOs (Named Executive Officers), with specific values for awards outstanding and unvested at year-end. The company is based in Gaithersburg, MD, and operates in the biological products sector.
Why It Matters
This filing provides transparency into how Novavax compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the specifics of executive compensation can sometimes signal underlying company performance or governance concerns.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for executive compensation)
- 20250620 — Conformed Period of Report (Date as of which the report is considered)
- 20250429 — Filing Date (Date the DEF 14A was submitted)
Key Players & Entities
- Novavax Inc. (company) — Filer of the DEF 14A
- John C. Jacobs (person) — Member, Named Executive Officer
- Stanley C. Erck (person) — Member, Named Executive Officer
- Gaithersburg, MD (location) — Company headquarters
FAQ
What were the total equity awards granted to PEOs in 2024?
The filing indicates equity awards were granted to PEOs for the period 2024-01-01 to 2024-12-31, with details on year-end values of outstanding and unvested awards.
What were the total equity awards granted to Non-PEO NEOs in 2024?
The filing indicates equity awards were granted to Non-PEO NEOs for the period 2024-01-01 to 2024-12-31, with details on year-end values of outstanding and unvested awards.
What is the company's primary business?
Novavax Inc. is in the Biological Products (No Diagnostic Substances) industry, SIC code 2836.
When is Novavax's fiscal year end?
Novavax's fiscal year ends on December 31st.
Who are the named executive officers mentioned in relation to past compensation periods?
Stanley C. Erck and John C. Jacobs are mentioned as members in relation to compensation periods including 2021, 2022, 2023, and 2024.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by John C. Jacobs regarding NOVAVAX INC (NVAX).